These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 21778575)

  • 1. Molecular profiling of triple negative breast cancer.
    Ma CX; Luo J; Ellis MJ
    Breast Dis; 2010; 32(1-2):73-84. PubMed ID: 21778575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Triple-negative breast carcinoma--rewiev of current literature].
    Rubovszky G; Udvarhelyi N; Horváth Z; Láng I; Kásler M
    Magy Onkol; 2010 Dec; 54(4):325-35. PubMed ID: 21163763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.
    Venkitaraman R
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):199-207. PubMed ID: 20131996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of triple negative breast cancer (TNBC): current options and future perspectives.
    De Laurentiis M; Cianniello D; Caputo R; Stanzione B; Arpino G; Cinieri S; Lorusso V; De Placido S
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S80-6. PubMed ID: 21129616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
    Nanda R
    Semin Oncol; 2011 Apr; 38(2):254-62. PubMed ID: 21421115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular stratification of triple-negative breast cancers.
    Perou CM
    Oncologist; 2011; 16 Suppl 1():61-70. PubMed ID: 21278442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic triple-negative breast cancer.
    Rakha EA; Chan S
    Clin Oncol (R Coll Radiol); 2011 Nov; 23(9):587-600. PubMed ID: 21524569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current treatment options in triple negative breast cancer.
    Rodler E; Korde L; Gralow J
    Breast Dis; 2010; 32(1-2):99-122. PubMed ID: 21778572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept.
    Linn SC; Van 't Veer LJ
    Eur J Cancer; 2009 Sep; 45 Suppl 1():11-26. PubMed ID: 19775601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of triple negative breast cancer.
    Oakman C; Viale G; Di Leo A
    Breast; 2010 Oct; 19(5):312-21. PubMed ID: 20382530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promising therapeutic options in triple-negative breast cancer.
    Bilici A; Arslan C; Altundag K
    J BUON; 2012; 17(2):209-22. PubMed ID: 22740196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular stratification of triple-negative breast cancers.
    Perou CM
    Oncologist; 2010; 15 Suppl 5():39-48. PubMed ID: 21138954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA copy number alterations and expression of relevant genes in triple-negative breast cancer.
    Han W; Jung EM; Cho J; Lee JW; Hwang KT; Yang SJ; Kang JJ; Bae JY; Jeon YK; Park IA; Nicolau M; Jeffrey SS; Noh DY
    Genes Chromosomes Cancer; 2008 Jun; 47(6):490-9. PubMed ID: 18314908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation.
    Karn T; Pusztai L; Ruckhäberle E; Liedtke C; Müller V; Schmidt M; Metzler D; Wang J; Coombes KR; Gätje R; Hanker L; Solbach C; Ahr A; Holtrich U; Rody A; Kaufmann M
    Eur J Cancer; 2012 Jan; 48(1):12-23. PubMed ID: 21741824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple-negative breast cancer: making the most of a misnomer.
    McCarthy N; Mitchell G; Bilous M; Wilcken N; Lindeman GJ
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):145-55. PubMed ID: 22524573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.
    de Ronde JJ; Hannemann J; Halfwerk H; Mulder L; Straver ME; Vrancken Peeters MJ; Wesseling J; van de Vijver M; Wessels LF; Rodenhuis S
    Breast Cancer Res Treat; 2010 Jan; 119(1):119-26. PubMed ID: 19669409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mouse models of triple negative [basal-like/claudin low] breast cancer.
    Herschkowitz JI; Lubet R
    Breast Dis; 2010; 32(1-2):63-71. PubMed ID: 21965308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the difference between triple-negative and basal breast cancers?
    Seal MD; Chia SK
    Cancer J; 2010; 16(1):12-6. PubMed ID: 20164685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
    Kurebayashi J
    Breast Cancer; 2009; 16(4):275-80. PubMed ID: 19408071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.
    Diaz LK; Cryns VL; Symmans WF; Sneige N
    Adv Anat Pathol; 2007 Nov; 14(6):419-30. PubMed ID: 18049131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.